Výsledky vyhledávání

Akademický článek

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

Autor: Caroline Schwarz, Raphael Schubert, Michael Schwarz, Angelika Schütz, Anika Jenke, David Bauer, Benjamin Steinwender, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler

Publikováno v: Journal of Virus Eradication, Vol 9, Iss 3, Pp 100338- (2023)

Background: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). Method

Externí odkaz: https://doaj.org/article/9e359741ff324bdfa4cf048f26ac6ca4

Zobrazit plný text záznamu

Akademický článek

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

Autor: Caroline Schmidbauer, Michael Schwarz, Angelika Schütz, Raphael Schubert, Cornelia Schwanke, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler

Publikováno v: PLoS ONE, Vol 16, Iss 6, p e0252274 (2021)

Background & aimsWe evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) fa

Externí odkaz: https://doaj.org/article/9b1adb9e5f5f407f81472ebb32218777

Zobrazit plný text záznamu

Akademický článek

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.

Autor: Caroline Schmidbauer, Raphael Schubert, Angelika Schütz, Cornelia Schwanke, Julian Luhn, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler

Publikováno v: PLoS ONE, Vol 15, Iss 3, p e0229239 (2020)

BACKGROUND:Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates >90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) a

Externí odkaz: https://doaj.org/article/82aeb993816349b19db8a49b1b40eaa0

Zobrazit plný text záznamu

Plný text ve formátu HTML

Combining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy

Autor: Michael Schwarz, Caroline Schwarz, Angelika Schütz, Cornelia Schwanke, Eva Krabb, Raphael Schubert, Sophie-Therese Liebich, David Bauer, Lukas Burghart, Leonard Brinkmann, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7b84584e6307dd76688948c11344dfc
https://doi.org/10.2139/ssrn.4231218

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání